ARCHIVES

Drugs and Targets: Blincyto granted accelerated approval in R/R ALL

This article is from The Cancer Letter archive.

Vol. 40 No. 45 | December 5, 2014

Download PDF Visit The Full Archive

Related Articles

FDA’s Handling Of UFT Raises Questions About Agency’s Isolation, Grasp Of Science.

July 21, 2000

NIH “RFA Game” Defeats Purpose Of OAM, Advisor Says

September 30, 1994

Aromasin Approved By FDA For ER+ Early Breast Cancer

October 28, 2005

Medenica Trial Begins In South Carolina

February 10, 1995

GAO Suggests No Limit On Indirect Costs But Ceiling On Total Costs

September 7, 1979

In Brief: MSK Opens Campaign On Colorectal Cancer Early Detection NIH Symposium Dedicates Cyclotron

August 28, 1987